Muna Therapeutics ApS has patented new triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes and obesity, among others.

Astrazeneca AB has patented new proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors reported to be useful for the treatment of cardiovascular disorders.

Mitochondrial glutaminase kidney isoform (GLS, GLS1) inhibitors have been detailed in a Sitryx Therapeutics Ltd. patent. They are described as potentially useful for the treatment of fibrosis and inflammatory disorders.

Humanwell Pharmaceutical US Inc. has disclosed new potassium voltage-gated channel subfamily KQT member 2 (KCNQ2; Kv7.2) and Kv7.3 activators. They are described as potentially useful for the treatment of epilepsy, pain, depression, bipolar disorder, amyotrophic lateral sclerosis and neurodegeneration.

Work at Aligos Therapeutics Inc. has led to the discovery of new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of hepatocellular carcinoma and hepatitis B.

Blossomhill Therapeutics Inc. have identified 7-azaindazole macrocycles acting as ALK tyrosine kinase receptor (mutant) inhibitors potentially useful for the treatment of cancer.

Immuse Therapeutics Inc. has described E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Dem Biopharma Inc. has divulged G-protein coupled receptor 84 (GPR84) agonists and phagocytosis inducers reported to be useful for the treatment of cancer, infections, neurological disorders and rheumatoid arthritis.

Neuron23 Inc. has identified non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of autoimmune disease, endocrine disorders, inflammatory disorders and multiple sclerosis.

Vanqua Bio Inc. has synthesized C5a anaphylatoxin chemotactic receptor 1 (C5aR; CD88) antagonists reported to be useful for the treatment of autoimmune disease, cancer, infections, and cardiovascular, inflammatory and neurological disorders.